Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E YM-254890 uveal melanoma no benefit detail...
NRAS Q61K YM-254890 uveal melanoma no benefit detail...
PALB2 mutant N/A uveal melanoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00489944 Phase II Cisplatin + Sunitinib + Tamoxifen Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status USA 0
NCT01200238 Phase II Ganetespib STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed USA 0
NCT01430416 Phase I Sotrastaurin Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Completed USA | NLD | GBR | FRA 0
NCT01471054 Phase II Dexamethasone intravitreal implant Bevacizumab Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Terminated USA 0
NCT01585194 Phase II Ipilimumab Nivolumab Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma Active, not recruiting USA 0
NCT01587352 Phase II Vorinostat Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Active, not recruiting USA 0
NCT01835145 Phase II Dacarbazine Temozolomide Cabozantinib Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye Completed USA | CAN 0
NCT01974752 Phase III Dacarbazine + Selumetinib Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL 3
NCT01979523 Phase II Trametinib Trametinib + Uprosertib Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed USA | GBR | FRA 0
NCT02068586 Phase II Valproic acid Sunitinib Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma Active, not recruiting USA 0
NCT02223819 Phase II Crizotinib Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Completed USA 0
NCT02273219 Phase I Alpelisib + Sotrastaurin Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Completed USA 0
NCT02359851 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Terminated USA 0
NCT02363283 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed USA 0
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Completed USA 0
NCT02570308 Phase I Tebentafusp A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Completed USA | GBR | ESP | DEU | CAN 0
NCT02601378 Phase I IDE196 + Siremadlin IDE196 A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Terminated USA | NLD | FRA | ESP | AUS 1
NCT02645149 Phase II Trametinib Pazopanib Ceritinib Ribociclib + Trametinib Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) Recruiting AUS 0
NCT02768766 Phase I Selumetinib Intermittent Selumetinib for Uveal Melanoma Completed USA 0
NCT02913417 Phase Ib/II Ipilimumab + Nivolumab + Yttrium-90 microsphere therapy Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Unknown status USA 0
NCT03022565 Phase I Vorinostat Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Withdrawn 0
NCT03052127 Phase I AU-011 Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma Completed USA 0
NCT03068624 Phase I Aldesleukin + Cyclophosphamide + Ipilimumab Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT03070392 Phase II Dacarbazine Ipilimumab Pembrolizumab Tebentafusp Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03408587 Phase I Coxsackievirus A21 + Ipilimumab CAVATAK and Ipilimumab in Uveal Melanoma Metastatic to the LIver (VLA-024 CLEVER) (CLEVER) Completed USA 0
NCT03417739 Phase II Ulixertinib A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Active, not recruiting USA 0
NCT03712904 Phase II Aflibercept Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Completed USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | ESP 1
NCT03922880 Phase I ADI-PEG 20 + Ipilimumab + Nivolumab Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma Completed USA 0
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting USA | CAN | AUS 0
NCT04109456 Phase I BI 853520 + Cobimetinib BI 853520 IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma Recruiting USA | AUS 0
NCT04116320 Phase I unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) Active, not recruiting USA 0
NCT04130516 Phase Ib/II LNS8801 LNS8801 + Pembrolizumab Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Recruiting USA 0
NCT04283890 Phase Ib/II Melphalan Ipilimumab + Melphalan + Nivolumab PHP and Immunotherapy in Metastasized UM Recruiting NLD 0
NCT04328844 Phase I IOA-244 A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers Active, not recruiting ITA | GBR 0
NCT04336241 Phase I Nivolumab + RP2 RP2 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Recruiting GBR | ESP 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04551352 Phase I RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Completed USA | ESP | CAN | BEL | AUS 1
NCT04552223 Phase II Nivolumab + Relatlimab Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT04589832 Phase Ib/II Entrectinib + PAC-1 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma Terminated USA 0
NCT04720417 Phase II Defactinib + RO5126766 Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT04879017 Phase I FHD-286 FHD-286 in Subjects With Metastatic Uveal Melanoma Terminated USA | NLD | FRA 0
NCT04935229 Phase I Ipilimumab + Nivolumab + SD-101 Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT04987996 Phase II Pembrolizumab Belapectin + Pembrolizumab GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients Withdrawn USA 0
NCT04993677 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 A Study of SEA-CD40 Given With Other Drugs in Cancers Active, not recruiting USA | FRA | ESP | DEU | CAN 1
NCT05004025 Phase I Ipilimumab + Nivolumab Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Recruiting USA 0
NCT05047536 Phase I KZR-261 KZR-261 in Subjects With Advanced Solid Malignancies Recruiting USA 0
NCT05077280 Phase II Ipilimumab + Nivolumab A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Recruiting USA 0
NCT05170334 Phase II Belinostat + Binimetinib Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Recruiting USA 0
NCT05187884 Phase II IDE196 Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM) Active, not recruiting AUS 0
NCT05282901 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (PLUME) Recruiting FRA 0
NCT05308901 Phase II Lenvatinib + Pembrolizumab Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naive Metastatic Uveal Melanoma Recruiting USA 0
NCT05315258 Phase II Tebentafusp Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Recruiting GBR 0
NCT05323045 Phase I BYON3521 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 Recruiting NLD | ITA | GBR | BEL 0
NCT05415072 Phase Ib/II DYP688 A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Recruiting USA | NLD | FRA | ESP | DEU | AUS 1
NCT05482074 Phase II Olaparib Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Withdrawn 0
NCT05524935 Phase II Olaparib + Pembrolizumab Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Recruiting USA 0
NCT05542342 Phase II Sitravatinib + Tislelizumab Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (SITISVEAL) Active, not recruiting ESP 0
NCT05576077 Phase I Pembrolizumab + TBio-4101 A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) Recruiting USA | CAN 0
NCT05607095 Phase I Lifileucel Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma Recruiting USA 0
NCT05907954 Phase II IDE196 (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Recruiting USA | NLD | ITA | GBR | FRA | DEU | CAN | AUS 0
NCT05987332 Phase II Dacarbazine Pembrolizumab Ipilimumab + Nivolumab Crizotinib + IDE196 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT06070012 Phase II Tebentafusp Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma Not yet recruiting USA 0
NCT06121180 Phase II Aflibercept + Cemiplimab Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma Recruiting USA 0